Novel Antibody Therapeutics Congress

Do not hesitate to contact us if you want to meet our team during this meeting.

Do not miss the presentation on October 10, 2019 at 09:00 "Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamm9delta2 T cells"

by Prof. René Hoet, PhD, CSO, ImCheck Therapeutics

ImCheck Therapeutics is advancing the first activating butyrophilin BTN3A (CD277) antibody towards the clinic. The humanized antibody to BTN3A, ICT01, specifically activates human gamma9delta2 T cells in vitro and in vivo and is planned to enter Phase I studies in early 2020. Additionally, therapeutic antibodies against 5 novel butyrophilins are currently validated. This opens a completely new space that is clearly different from the current B7/CD28 superfamily targets and has the potential to become the next generation immune checkpoint modulators.